Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted? von BAHLIS, N. J, LAZARUS, H. M

Volltext

Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial von Bahlis, N J, Corso, A, Mugge, L-O, Shen, Z-X, Desjardins, P, Stoppa, A-M, Decaux, O, de Revel, T, Granell, M, Marit, G, Nahi, H, Demuynck, H, Huang, S-Y, Basu, S, Guthrie, T H, Ervin-Haynes, A, Marek, J, Chen, G, Facon, T

Volltext

MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents von Shah, M Y, Martinez-Garcia, E, Phillip, J M, Chambliss, A B, Popovic, R, Ezponda, T, Small, E C, Will, C, Phillip, M P, Neri, P, Bahlis, N J, Wirtz, D, Licht, J D

Volltext

Influence of comorbidities on transplant outcomes in patients aged 50 years or more after myeloablative conditioning incorporating fludarabine, BU and ATG von El Kourashy, S, Williamson, T, Chaudhry, M A, Savoie, M L, Turner, A R, Larratt, L, Storek, J, Bahlis, N J, Brown, C B, Yang, M, Quinlan, D, Geddes, M, Zacarias, N, Daly, A, Duggan, P, Stewart, D A, Russell, J A

Volltext

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma von Dimopoulos, Meletios A., Oriol, Albert, Nahi, Hareth, San-Miguel, Jesus, Bahlis, Nizar J., Usmani, Saad Z., Rabin, Neil, Orlowski, Robert Z., Komarnicki, Mieczyslaw, Suzuki, Kenshi, Plesner, Torben, Yoon, Sung-Soo, Ben Yehuda, Dina, Richardson, Paul G., Goldschmidt, Hartmut, Reece, Donna, Lisby, Steen, Khokhar, Nushmia Z., O’Rourke, Lisa, Chiu, Christopher, Qin, Xiang, Guckert, Mary, Ahmadi, Tahamtan, Moreau, Philippe

Volltext

Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone... von San Miguel, Jesus F, Weisel, Katja C, Song, Kevin W, Delforge, Michel, Karlin, Lionel, Goldschmidt, Hartmut, Moreau, Philippe, Banos, Anne, Oriol, Albert, Garderet, Laurent, Cavo, Michele, Ivanova, Valentina, Alegre, Adrian, Martinez-Lopez, Joaquin, Chen, Christine, Renner, Christoph, Bahlis, Nizar Jacques, Yu, Xin, Teasdale, Terri, Sternas, Lars, Jacques, Christian, Zaki, Mohamed H, Dimopoulos, Meletios A

Volltext

Minimal residual disease (MRD) assessment by flow cytometry after ASCT for AL amyloidosis: are we there yet? von Lee, H, Duggan, P, Neri, P, Tay, J, Bahlis, N J, Jimenez-Zepeda, V H

Volltext

P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B‐CELL MATURATION ANTIGEN (BCMA)‐CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR... von Lesokhin, A. M., Arnulf, B., Niesvizky, R., Mohty, M., Bahlis, N. J., Tomasson, M. H., Rodrίguez‐Otero, P., Quach, H., Raje, N. S., Iida, S., Raab, M.‐S., Czibere, A., Sullivan, S., Leip, E., Viqueira, A., Leleu, X.

Volltext

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma von Dimopoulos, Meletios A, Oriol, Albert, Nahi, Hareth, San-Miguel, Jesus, Bahlis, Nizar J, Usmani, Saad Z, Rabin, Neil, Orlowski, Robert Z, Komarnicki, Mieczyslaw, Suzuki, Kenshi, Plesner, Torben, Yoon, Sung-Soo, Ben Yehuda, Dina, Richardson, Paul G, Goldschmidt, Hartmut, Reece, Donna, Lisby, Steen, Khokhar, Nushmia Z, O’Rourke, Lisa, Chiu, Christopher, Qin, Xiang, Guckert, Mary, Ahmadi, Tahamtan, Moreau, Philippe

Volltext

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma von Moreau, Philippe, Masszi, Tamás, Grzasko, Norbert, Bahlis, Nizar J, Hansson, Markus, Pour, Ludek, Sandhu, Irwindeep, Ganly, Peter, Baker, Bartrum W, Jackson, Sharon R, Stoppa, Anne-Marie, Simpson, David R, Gimsing, Peter, Palumbo, Antonio, Garderet, Laurent, Cavo, Michele, Kumar, Shaji, Touzeau, Cyrille, Buadi, Francis K, Laubach, Jacob P, Berg, Deborah T, Lin, Jianchang, Di Bacco, Alessandra, Hui, Ai-Min, van de Velde, Helgi, Richardson, Paul G

Volltext

P05: DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM... von Dimopoulos, MA, Oriol, A, Nahi, H, San‐Miguel, J, Bahlis, NJ, Usmani, SZ, Rabin, N, Orlowski, RZ, Suzuki, K, Plesner, T, Yoon, SS, Ben Yehuda, D, Richardson, PG, Goldschmidt, H, Reece, D, Ahmadi, T, Qin, X, Garvin Mayo, W, Gai, X, Carey, J, Carson, R, Moreau, P

Volltext

EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA von Solh, M, Bahlis, NJ, Raje, NS, Costello, CL, Dholaria, B, Levy, MY, Tomasson, MH, Dube, H, Damore, MA, Lon, HK, Basu, C, Skoura, A, Chan, EM, Trudel, S, Jakubowiak, A, Chu, MP, Gasparetto, C, Dalovisio, A, Sebag, M, Lesokhin, AM

Volltext

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial von Lonial, Sagar, Prof, Weiss, Brendan M, Prof, Usmani, Saad Z, Prof, Singhal, Seema, Prof, Chari, Ajai, Prof, Bahlis, Nizar J, Prof, Belch, Andrew, Prof, Krishnan, Amrita, Prof, Vescio, Robert A, Prof, Mateos, Maria Victoria, Prof, Mazumder, Amitabha, Prof, Orlowski, Robert Z, Prof, Sutherland, Heather J, Prof, Bladé, Joan, Prof, Scott, Emma C, Prof, Oriol, Albert, MD, Berdeja, Jesus, MD, Gharibo, Mecide, Prof, Stevens, Don A, MD, LeBlanc, Richard, Prof, Sebag, Michael, Prof, Callander, Natalie, Prof, Jakubowiak, Andrzej, Prof, White, Darrell, Prof, de la Rubia, Javier, Prof, Richardson, Paul G, Prof, Lisby, Steen, MD, Feng, Huaibao, PhD, Uhlar, Clarissa M, PhD, Khan, Imran, MD, Ahmadi, Tahamtan, MD, Voorhees, Peter M, Prof

Volltext

Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone von Dimopoulos, Meletios A, Weisel, Katja C, Song, Kevin W, Delforge, Michel, Karlin, Lionel, Goldschmidt, Hartmut, Moreau, Philippe, Banos, Anne, Oriol, Albert, Garderet, Laurent, Cavo, Michele, Ivanova, Valentina, Alegre, Adrian, Martinez-Lopez, Joaquin, Chen, Christine, Spencer, Andrew, Knop, Stefan, Bahlis, Nizar J, Renner, Christoph, Yu, Xin, Hong, Kevin, Sternas, Lars, Jacques, Christian, Zaki, Mohamed H, San Miguel, Jesus F

Volltext

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma von Usmani, Saad Z., Weiss, Brendan M., Plesner, Torben, Bahlis, Nizar J., Belch, Andrew, Lonial, Sagar, Lokhorst, Henk M., Voorhees, Peter M., Richardson, Paul G., Chari, Ajai, Sasser, A.Kate, Axel, Amy, Feng, Huaibao, Uhlar, Clarissa M., Wang, Jianping, Khan, Imran, Ahmadi, Tahamtan, Nahi, Hareth

Volltext

New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma von Neri, Paola, Bahlis, Nizar J, Lonial, Sagar

Volltext

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma von Facon, Thierry, Dimopoulos, Meletios A., Dispenzieri, Angela, Catalano, John V., Belch, Andrew, Cavo, Michele, Pinto, Antonello, Weisel, Katja, Ludwig, Heinz, Bahlis, Nizar J., Banos, Anne, Tiab, Mourad, Delforge, Michel, Cavenagh, Jamie D., Geraldes, Catarina, Lee, Je-Jung, Chen, Christine, Oriol, Albert, De La Rubia, Javier, White, Darrell, Binder, Daniel, Lu, Jin, Anderson, Kenneth C., Moreau, Philippe, Attal, Michel, Perrot, Aurore, Arnulf, Bertrand, Qiu, Lugui, Roussel, Murielle, Boyle, Eileen, Manier, Salomon, Mohty, Mohamad, Avet-Loiseau, Herve, Leleu, Xavier, Ervin-Haynes, Annette, Chen, Guang, Houck, Vanessa, Benboubker, Lotfi, Hulin, Cyrille

Volltext

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX von Dimopoulos, Meletios A, San-Miguel, Jesus, Belch, Andrew, White, Darrell, Benboubker, Lotfi, Cook, Gordon, Leiba, Merav, Morton, James, Ho, P Joy, Kim, Kihyun, Takezako, Naoki, Moreau, Philippe, Kaufman, Jonathan L, Sutherland, Heather J, Lalancette, Marc, Magen, Hila, Iida, Shinsuke, Kim, Jin Seok, Prince, H Miles, Cochrane, Tara, Oriol, Albert, Bahlis, Nizar J, Chari, Ajai, O' Rourke, Lisa, Wu, Kaida, Schecter, Jordan M, Casneuf, Tineke, Chiu, Christopher, Soong, David, Sasser, A Kate, Khokhar, Nushmia Z, Avet-Loiseau, Hervé, Usmani, Saad Z

Volltext

Ascorbic acid enhances arsenic trioxide–induced cytotoxicity in multiple myeloma cells von Grad, Jennifer M., Bahlis, Nizar J., Reis, Isildinha, Oshiro, Marc M., Dalton, William S., Boise, Lawrence H.

Volltext

Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial von Dimopoulos, Meletios A, Oriol, Albert, Nahi, Hareth, San-Miguel, Jesus, Bahlis, Nizar J, Usmani, Saad Z, Rabin, Neil, Orlowski, Robert Z, Suzuki, Kenshi, Plesner, Torben, Yoon, Sung-Soo, Ben Yehuda, Dina, Richardson, Paul G, Goldschmidt, Hartmut, Reece, Donna, Ahmadi, Tahamtan, Qin, Xiang, Garvin Mayo, Wendy, Gai, Xue, Carey, Jodi, Carson, Robin, Moreau, Philippe

Volltext